A Phase I Study of Entinostat in combination with Enzalutamide for treatment of patients with castration-resistant prostate cancer (CRPC)

Objectives:

  1. Determine the safe dose of Entinostad when given in combination with Enzalutamide in CRPC patients
  2. Determine the safety profiles of the combination of Entinostat and Enzalutamide

Candidates: Patients with Castration-Resistant Prostate Cancer will participate in this phase I study by taking enzalutamide daily and the study drug Entinostat once every 7 days.

Clinical Program: Urological Oncology Program
Cancer Type & Condition: Prostate Cancer
Principal Investigator: Jianqing Lin
Contact Info: 2029940450